N4 PHARMA PLC — Director's Dealing 2015

May 18, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5346N

Verona Pharma PLC

18 May 2015

Verona Pharma plc

("Verona Pharma" or the "Company")

Director Dealings

18 May 2015, Cardiff - Verona Pharma plc (AIM: VRP) today received notification that on 15 and 18 May 2015 Directors of the Company purchased ordinary shares of 0.1 pence each of the Company ("Ordinary Shares"). The details of the trades are shown in the table below.

Director	Ordinary Shares Purchased	Date	Average Price (p)	Total interest in the Company	As a % of the total share capital
Dr. David Ebsworth	300,000	18/05/2015	3.50	3,579,774	0.35%
Dr. Jan-Anders Karlsson	135,000	15/05/2015	3.40	2,870,000	0.28%
Biresh Roy	150,000	18/05/2015	3.50	900,000	0.09%

-Ends-

For further information please contact:

Verona Pharma plc	Tel: +44 (0) 20 3283 4200
Jan-Anders Karlsson, CEO
N+1 Singer	Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer
FTI Consulting	Tel: +44 (0)20 3727 1000
Julia Phillips / Simon Conway

Notes to Editors

About Verona Pharma plc

Verona Pharma plc is a UK-based clinical stage biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD, asthma and cystic fibrosis. Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase II trials as a nebulised treatment for acute exacerbations of COPD in the hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both bronchodilator and anti-inflammatory effects, which are essential to the improvement of patients with COPD and asthma. Verona Pharma is also building a broader franchise around RPL554 to maximise its value, both to patients and to investors. This includes the very significant markets for COPD and asthma maintenance therapy. The Company is also exploring the potential of the drug in different diseases, such as cystic fibrosis, where it is in pre-clinical testing. 

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSSFIFDAFISEDI

//<![CDATA[$.ajaxSetup({headers: {'__RequestVerificationToken':'167DSOQFPZT6aWMN7Xk-Lb3iRArCK2eRicp6w6kvMBaUOiHJ-7-6ALRZ-8ShE74udvuVjDZCHGwi9QmCBpoiHoo42vAB7rLXji0_8VJNC681:0tM2peYRUBmCpid9VXsG105UimHHkvuy5iGpHeLWJqeUlMGAMYs5bbMM66XlTbU6JJVaU-4tAUu_FLmReGZSURV9tTtdAad564Xixw5h3c41'}});//]]>